Contact Us
Chengguan District, Lanzhou, Gansu, China
© 2025 Jeifer Pharmaceutical, All Right
Reserved.
(2R)-2-Deoxy-2-Fluoro-2-Methyl-D-Erythro-Pentonic Acid-G-Lactone 3,5-Bis(4-Chlorobenzoate) BP EP USP Pharma Grade belongs to a class of fine chemicals known for their use in advanced pharmaceutical manufacturing and research. Featuring the combination of deoxy, fluoro, and methyl functionalization on a D-erythro-pentonic acid lactone backbone, coupled with two para-chlorobenzoate groups, this compound represents an intersection of synthetic ingenuity and purposeful molecular design. Its structure and specific molecular modifications open up precise pathways to achieving greater selectivity, stability, and reactivity, attributes scientists and manufacturers are always chasing in new drug development. The BP, EP, and USP tags reflect compliance with British, European, and United States Pharmacopeias, linking trust and transparency to every batch sourced and handled in regulated laboratories and production facilities.
The chemical structure builds around a pentonic acid-derived lactone ring, substituted at the 2-position with both fluorine and methyl groups. Grafting two 4-chlorobenzoate moieties at the 3 and 5 positions brings not only increased hydrophobicity but also manipulation potential in downstream transformation reactions. The molecular formula details the exact arrangement: C21H15Cl2FO6 shapes the complexity, with a molecular weight approaching significant thresholds for many pharmaceutical APIs and advanced intermediates. These features allow researchers not only to anticipate reactivity and behavior in laboratory syntheses but also to engineer improved pharmacokinetics and metabolic stability, attributes crucial for bioactive molecule optimization.
In daily practice, product characterization means more than just knowing a molecular formula. Most often, (2R)-2-Deoxy-2-Fluoro-2-Methyl-D-Erythro-Pentonic Acid-G-Lactone 3,5-Bis(4-Chlorobenzoate) shows up as a crystalline solid, sometimes appearing as a fine, dense powder or in flakes. Handling this compound brings immediate tactile recognition; crystals suggest purity and batch integrity, while any observable amorphous form signals the need for further quality assessment. Density runs near 1.45 g/cm³, depending on the level of hydration and form. Unlike bulk chemicals with gritty or coarse profiles, the refined crystals here speak of advanced purification and tight process control. Storage usually takes place in airtight containers away from sunlight to pin down degradation and moisture intrusion, reflecting a chemistry lab’s day-to-day reality where loss of material means both wasted cost and research delay.
Manufacturers and importers will spot (2R)-2-Deoxy-2-Fluoro-2-Methyl-D-Erythro-Pentonic Acid-G-Lactone 3,5-Bis(4-Chlorobenzoate) under the HS Code designated for organic pharmaceutical intermediates, streamlining global supply chain tracing and import/export documentation. Each batch carries a certificate of analysis outlining minimum purity—most suppliers won’t settle for less than 98%. Professional experience teaches that substances used under regulated pharmacopeia must not contain detectable levels of heavy metals, residual solvents, or microbial contamination, as even minor deviations can sabotage synthetic yield or clinical applicability. Water content and melting point get checked regularly to catch storage or shipping-induced changes, both signs of proper inventory management.
Hazard and safety assessment always rides alongside any chemical supply. The inclusion of halogens and aromatic groups like chlorobenzoate brings increased acute toxicity potentials. Any misstep leads to exposure via skin, eyes, or inhalation during weighing or transfer, underscoring why personal protective equipment and a well-calibrated fume hood can’t be afterthoughts. I have worked in enough synthesis labs to recall sharply the odd scent halos and irritation from poorly handled reagents; ignoring safety protocols isn’t an option. Storage under inert atmosphere keeps degradation and volatility at bay, and safety datasheets always recommend not just gloves but proper respiratory protection during clean-up or accidental spillage. In case of fire, knowing the flash point and proper extinguishing agents is critical, since compounds with aromatic and halogen content could produce toxic gases if mishandled in an emergency.
For pharmaceutical chemists, sourcing compliant pharmaceutical-grade intermediates is pivotal. The rare combination of deoxy, fluoro, and methyl modifications enhances biological activity, solubility, and systemic stability, which aligns with strategies seen in modern medicinal chemistry to outmaneuver resistance or metabolic breakdown. Having access to (2R)-2-Deoxy-2-Fluoro-2-Methyl-D-Erythro-Pentonic Acid-G-Lactone 3,5-Bis(4-Chlorobenzoate) allows formulation chemists to push toward new chemical entities and prodrugs, broadening the portfolio of tools for unmet medical needs. Reliable supply chains and fully traceable raw materials insurance against batch-to-batch variability, a concern that has dogged too many programs aimed at bringing novel treatments to market. Stringent regulatory frameworks demand uniquely pure intermediates; compliance isn’t just a box on a form, but an underlying guarantee to patients and professionals relying on solid science and transparent sourcing.
Manufacturers and research labs receive this compound in various forms tailored for downstream processing. Flakes and fine powders load easily into reactors. Crystals support single-crystal X-ray diffraction experiments, expediting structural confirmation. Some suppliers ship in pre-weighed vials to minimize exposure and simplify workflow for quality control. Bulk shipments arrive in sealed liner drums or high-density polyethylene canisters, depending on target purity and lot size. Researchers concerned about solubility opt for solution concentrates in compatible solvents, allowing precise dosing and immediate reaction startup. Broad demand shapes form selection, always targeting the unique needs of both small-scale academic teams and industrial continuous synthesis plants.
Sourcing, storing, and handling innovative pharmaceutical intermediates brings daily challenges. Investing in staff training ensures accidents don’t sour hard-won project momentum. Industries making real headway in pharmaceuticals use digital batch tracing and third-party audits to guarantee compliance. From my own projects, supporting partnerships with transparent suppliers reduced raw material risk and opened the door to faster regulatory filing when hit with audits. Facilities equipped with advanced environmental controls cut down on degradation and extend shelf-life, saving costs and keeping delivery schedules on track. Newer analytical tools like ultra-high performance liquid chromatography catch impurities faster and tighter than ever before, pushing standards higher for process optimization. Clear labeling and accurate certificates matter, especially when delivering products that may eventually touch patients’ lives. Regulatory shifts mean companies cannot rest on old practices; preparedness and ongoing quality improvement make the difference between a reliable partner and a potential bottleneck in drug development.
Chengguan District, Lanzhou, Gansu, China
